Samarth Kulkarni - 29 Jun 2022 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Executive Officer, Director
Signature
/s/ James R. Kasinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
29 Jun 2022
Net transactions value
-$1,225,612
Form type
4
Filing time
01 Jul 2022, 18:00:17 UTC
Previous filing
13 Jun 2022
Next filing
05 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRSP Common Shares Options Exercise $314,250 +25,000 +8.6% $12.57 315,279 29 Jun 2022 Direct
transaction CRSP Common Shares Sale $1,244,454 -20,260 -6.4% $61.42 295,019 29 Jun 2022 Direct F1, F2
transaction CRSP Common Shares Sale $295,407 -4,740 -1.6% $62.32 290,279 29 Jun 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Stock Option (Right to Buy) Options Exercise $0 -25,000 -75% $0.000000 8,333 29 Jun 2022 Common Shares 25,000 $12.57 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.99 to $61.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.00 to $62.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 This option was granted on July 15, 2016 with respect to 93,333 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016.

Remarks:

Exhibit 24 - Power of Attorney